Human IL-27 protein (Recombinant) (STJP000659)
SPECIFICATIONS
HostCHO Cells
ConjugationUnconjugated
ImmunogenDNA sequence encoding mature chain of Human IL-27A fused toDNA sequence encoding mature chain of Human IL-27B via a linker chain anda C-terminal polyHis tag was expressed in CHO cells. NA
General Information
| Short Description | Recombinant-Human IL-27-protein was developed from cho cells. For use in research applications. |
| Host | CHO Cells |
| Note | STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Conjugation | Unconjugated |
| Dilution Range | Spin the vial and reconstite in distilled water to a concentration not less than 0.1 mg/mL. This can then be diluted into other buffers. |
| Formulation | Lyophilised from 0.2 Mu m filtered PBS solution pH 7.4. |
| Storage Instruction | Can be stored in working aliquots at 2°C-8°C C for one month, or at-20°C C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles. NA |
| Endotoxin | Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
| Immunoreactivity | The activity was determined by its ability to bind recombinant Human IL-27RA with a linear range of 60-1000 ng/ml in functional ELISA. NA |
Target Information
| Gene Symbol | IL27 |
| Gene ID | 246778 |
| Uniprot ID | IL27A_HUMAN |
| Immunogen | DNA sequence encoding mature chain of Human IL-27A fused toDNA sequence encoding mature chain of Human IL-27B via a linker chain anda C-terminal polyHis tag was expressed in CHO cells. NA |
| Immunogen Region | Mature chain |
Additional Info
| Tissue Specificity | Expressed in monocytes and in placenta. |
| Post Translational Modifications | O-glycosylated. |
| Function | Associates with EBI3 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which appears to be required but not sufficient for IL-27-mediated signal transduction. IL-27 potentiate the early phase of TH1 response and suppress TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. It suppresses the expression of GATA3, the inhibitor TH1 cells development. In CD8 T-cells, it activates STATs as well as GZMB. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL27 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed the development of pro-inflammatory Th17 cells via STAT1, it inhibits the development of anti-inflammatory inducible regulatory T-cells, iTreg, independently of STAT1. IL-27 also has an effect on cytokine production, it suppresses pro-inflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T-cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9. In vein endothelial cells, it induces IRF1/interferon regulatory factor 1 and increase the expression of MHC class II transactivator/CIITA with resulting up-regulation of major histocompatibility complex class II. IL-27 also demonstrates antiviral activity with inhibitory properties on HIV-1 replication. |
| Protein Name | Interleukin-27 Subunit AlphaIl-27 Subunit AlphaIl-27-AIl27-AInterleukin-30P28 |
| Database Links | Reactome: R-HSA-9020956 |
| Cellular Localisation | SecretedDoes Not Seem To Be Secreted Without Coexpression Of Ebi3 |
| Alternative Protein Names | Interleukin-27 Subunit Alpha proteinIl-27 Subunit Alpha proteinIl-27-A proteinIl27-A proteinInterleukin-30 proteinP28 proteinIL27 proteinIL27A proteinIL30 protein |
Information sourced from Uniprot.org